AISight Dx

by PathAI  · Based in United States → — Improving patient outcomes through its AI-powered pathology platform.
Pathology

Contact vendor for pricing information.
Regulatory Status Disclosed

Overview

It serves as a central hub for case and image management, integrating advanced AI algorithms to support laboratory operations, clinical workflows, and primary diagnosis in the US. The platform enables pathologists to intuitively view, interpret, share, and manage whole slide images, offering end-to-end workflow support. AISight Dx is built for interoperability, connecting with most major laboratory information systems (LIS) and various slide scanners, including Leica Aperio® GT 450 DX, Hamamatsu NanoZoomer® S360MD, Roche VENTANA® DP200 and DP600. It is also CE-IVDR certified for primary diagnosis in the EEA, UK, and Switzerland.

The system is AI-native, designed to seamlessly integrate PathAI’s own AI-powered tools and a growing list of over 40 third-party algorithms for use in research, workflow optimization, assisted scoring, and biomarker quantification. Key functionalities include intelligent case routing, automated assignment, real-time collaboration, and structured reporting, all aimed at optimizing operational efficiency and accelerating turnaround times. PathAI leverages extensive datasets, including over 20 million annotations from a network of over 550 pathologists, to rigorously train and validate its AI models, ensuring high diagnostic accuracy and consistency.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Cloud-native image management system
  • AI-powered workflow optimization (e.g., case prioritization, automated assignment)
  • High-performance whole slide image viewing and interpretation
  • Seamless integration of PathAI and third-party AI algorithms
  • Real-time multi-institutional collaboration (AISight Live)
  • Intelligent case routing and management
  • Structured reporting and voice-enabled reporting support
  • Interoperability with major LIS and slide scanners
  • Biomarker quantification and analysis
  • Flexible slide tray organization and ingestion flexibility

Use Cases

  • Primary diagnosis in clinical settings
  • Translational research and biomarker discovery
  • Drug development and clinical trials support
  • Digital pathology workflow management
  • Education and training
  • Quality control and assurance

What Physicians Need to Know

Whole Slide Image Support
AISight Dx is a cloud-native Image Management System (IMS) that enables pathologists to view, interpret, share, and manage whole slide images (WSIs) intuitively. It supports a wide range of use cases including diagnostics, research, education, and training. The platform is scanner-agnostic and ingests images from major scanners such as Hamamatsu NanoZoomer S360MD, Leica Aperio GT 450 DX, Roche VENTANA DP200 and DP600, and Philips UFS. It processes over 100 million whole-slide images, enabling scalable, efficient, and accurate digital pathology workflows.
Digital Pathology Integration
AISight Dx is an AI- and cloud-native solution designed for primary diagnosis, centralizing case and image management. It integrates AI directly into the slide viewer and beyond for next-generation efficiency through case prioritization, automated assignment, assisted reporting, and quality assurance. The platform supports a growing list of over 40 third-party algorithms from leading AI developers, fully embedded within the same viewer and across the entire workflow. It also offers real-time collaboration tools like AISight Live and asynchronous collaboration tools.
Stain Compatibility
AISight Dx supports standard H&E stained whole slide images for algorithms like TumorDetect and AIM-TumorCellularity. It also supports IHC stains for biomarker panels such as AIM-IHC Breast Panel (HER2, ER, PR, Ki-67) and AIM-PD-L1.
Biomarker Detection Capabilities
PathAI offers a broad Research Use Only (RUO) AI portfolio, including PathAssist Derm for dermatopathology, and biomarker panels such as AIM-PD-L1, AIM-MASH, and AIM-Breast. The AIM-IHC Breast Panel quantifies critical breast cancer biomarkers—HER2, ER, PR, and Ki-67. AISight Dx also supports third-party CE-IVD marked AI solutions for breast cancer biomarker analysis (HER2, ER/PR, Ki-67) and lung PD-L1 from partners like Mindpeak and Visiopharm.
Turnaround Time Impact
AISight Dx automates workflows, prioritizes urgent cases, and streamlines tasks, reducing manual effort and enabling efficient case management. It is designed to expedite response times and improve pathologist productivity, with integrated image management, synchronized multi-slide navigation, and annotation tools aiming to eliminate manual processes and facilitate quicker diagnostic outcomes. Digital pathology, in general, can cut turnaround times by approximately 30% by replacing manual slide handling, even before AI is introduced. AISight Consults, a workflow within AISight Dx, helps reduce reliance on glass slide shipment and manual coordination, supporting faster turnaround times for consultations.
CAP/CLIA Compliance
AISight Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland. It is compliant with HIPAA, GDPR, HITECH, SOC 2, and ISO 27001. The FDA clearance includes a Predetermined Change Control Plan (PCCP), allowing PathAI to implement major updates (e.g., new displays, scanners, file formats, browsers) without additional 510(k) submissions, ensuring compliance with FDA regulations for AI/ML-enabled medical devices.
Supported Cancer Types
AISight Dx supports AI applications for various cancer types. PathAI's RUO portfolio includes solutions for dermatopathology, and biomarker panels for breast and MASH. Third-party AI solutions available through AISight Dx include CE-IVD marked solutions for breast cancer (HER2, ER/PR, Ki-67) and lung PD-L1, as well as RUO assays for prostate, gastric, esophageal, urothelial cancers, and dermatopathology. DeepBio's DeepDx Prostate (CE-IVD marked) and DeepDx Breast (RUO) are also supported. Paige's AI suite includes solutions for Prostate, Breast, Colon, and Pan-Cancer. Primaa offers AI-powered diagnostic tools like Cleo Breast (CE-IVDR) and Cleo Skin (RUO). TumorDetect, an AI algorithm for case prioritization, identifies suspected tumors across solid tumors in breast, lung, prostate, colon, skin, stomach, duodenum, and esophagus. AIM-TumorCellularity is trained as a pan-carcinoma model across 14+ tumor types, including NSCLC, breast, CRC, melanoma, gastric, RCC, PDAC, prostate, DLBCL, ovarian, bladder, HNSCC, HCC, and SCLC.
Quantitative Analysis Features
The platform uses sophisticated AI algorithms to automatically analyze pathology slides, identify key markers, and quantify biomarkers (e.g., PD-L1, HER2). Features include automated tissue segmentation, detection of on-slide controls, and classification of invasive versus non-invasive cancer. AIM-TumorCellularity quantifies total area of tissue, total area of tumor, and percent tumor nuclei, and provides supporting results like area of cancer, stroma, necrosis, and cell counts. AISight Dx also provides automated measurements and case- and slide-level synthesis.
LIS Integration
AISight Dx is interoperable with most major Laboratory Information Systems (LIS) and scanners. PathAI offers AISight Link, a suite of integration solutions that provides bi-directional integration between a client's LIS and AISight. This enables automated order transmission from the LIS to AISight via HL7 messaging, real-time updates, secure image transfer and storage, intelligent pairing of WSIs with case metadata, and embedded LIS “punchout” links for direct access to AISight cases. This integration aims to streamline workflows, reduce data mismanagement, and minimize sample identification errors.
Physician Tip

Leverage AISight Dx's AI-powered case prioritization (e.g., TumorDetect) to focus on high-priority cases and potentially reduce turnaround times. Utilize the integrated third-party AI algorithms and PathAI's own biomarker panels for comprehensive quantitative analysis and enhanced diagnostic precision across various cancer types. Take advantage of the real-time collaboration tools and consult workflows to facilitate communication and streamline second opinions, especially for complex cases. Explore the automated reporting and structured reporting features to reduce manual entry and maintain diagnostic flow. For labs not yet fully digitized, AISight Dx supports consult workflows through manual or bulk upload, offering a practical entry point into digital pathology without requiring full LIS integration from day one.

AISight Dx is designed as an open AI ecosystem, supporting a growing list of over 40 third-party algorithms from leading AI developers, fully embedded within the same viewer. This includes solutions from partners like Mindpeak, Visiopharm, DeepBio, and Paige. AISight Link provides robust bi-directional integration with major LIS systems, ensuring seamless data flow and workflow synchronization. This open and integrated approach allows laboratories to maximize their AI deployments across multiple specialties and leverage advanced features within a unified platform.

Details

Category Pathology AI
Pricing Contact vendor for pricing information.
DeploymentCloud-native, browser-accessible SaaS.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Pathology

Support & Reliability

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AISight Dx

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for AISight Dx.

View all on YouTube

Frequently Asked Questions

AISight Dx is designed for seamless integration with most major Electronic Medical Record (EMR) systems through standard APIs, allowing for direct data import and export. This ensures that AI-generated insights can be easily accessed and documented within a physician's established workflow, minimizing disruption.
AISight Dx has received [specific regulatory approval, e.g., FDA clearance for its intended use as a diagnostic aid]. We adhere strictly to HIPAA regulations, employing robust encryption, access controls, and de-identification protocols to protect all patient health information.
Clinical trials have demonstrated AISight Dx achieves [specific accuracy metric, e.g., 95% sensitivity and 92% specificity] in identifying target conditions. However, like all diagnostic tools, it has limitations, including potential for false positives in certain edge cases or with suboptimal image quality, which are clearly outlined in our user manual.
AISight Dx offers enhanced speed and consistency compared to traditional manual diagnostic methods, often identifying subtle patterns that may be missed. While other AI tools exist, AISight Dx distinguishes itself through its [mention a unique feature, e.g., proprietary deep learning algorithms and extensive validation on diverse patient populations].
AISight Dx offers flexible pricing models, including subscription-based licensing per user or per study, tailored to facility size and usage volume. We provide detailed cost-benefit analyses to demonstrate potential savings through improved diagnostic efficiency and reduced need for follow-up tests, which can positively impact reimbursement.
AISight Dx is designed as a powerful assistive tool, not a replacement for clinical judgment. It provides physicians with augmented insights and a second opinion to enhance diagnostic accuracy and efficiency. The final diagnostic decision and treatment plan always remain under the physician's purview.
We provide comprehensive onboarding training sessions for all clinical staff, covering system navigation, interpretation of AI outputs, and best practices. Ongoing 24/7 technical support is available through dedicated channels, along with regular software updates and educational resources to ensure optimal utilization.

Related Tools

PathologyAILab
PathologyAILab
Lab & Diagnostics
PathologyAILab provides AI-enhanced digital pathology analysis and diagnostic insights for healthcare providers, utilizing a multi-agent AI system for faster, more accurate cytology results.
ArteraAI Breast
Artera
Clinical Decision Support & Reference
ArteraAI Breast is an AI-powered digital pathology tool that helps physicians assess the risk of distant metastasis in patients with early-stage HR+/HER2- breast cancer, aiding in personalized treatment decisions.
OS-SiA
OptraSCAN
Pathology AI
OptraSCAN is a California based digital pathology company, founded in 2017, that makes whole slide imaging scanners, AI-powered image analysis, and image management software for clinical labs, hospitals, and research institutions. Its products cover histology, cytology, and bacteriology workflows.
Indica Labs HALO AI
Indica Labs
Drug Discovery & Research
HALO AI is a deep-learning add-on for the HALO image analysis platform, helping users solve image analysis challenges in segmentation, classification, and phenotyping for research.
Perimeter Medical Imaging AI
Perimeter Medical Imaging AI
Clinical Decision Support & Reference
The Claire OCT System by Perimeter Medical Imaging AI uses Optical Coherence Tomography and AI to provide real-time, high-resolution tissue imaging during surgery to help identify cancerous tissue.
SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.

See all Pathology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-22 | First Added: 2026-04-22

Investors who backed AISight Dx

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.